来自超过10万个多种癌症早期检测试验的现实数据和临床经验
Marc Matrana1, Vershalee Shukla2, Dallas Kingsbury3
1Ochsner Cancer Institute, New Orleans, LA, USA.
Nature communications
|November 1, 2025
概括
针对多种癌症的早期检测 (MCED) 的新血液检测显示出现实世界的前景. 盖勒里测试在0.91%的个体中发现了癌症信号,有助于及时诊断和预测癌症起源.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 诊断 诊断 诊断 诊断
背景情况:
- 基于血液的多种癌症早期检测 (MCED) 提供了同时查多种癌症的潜力.
- 高积极的预测值对于有效的早期检测策略至关重要.
研究的目的:
- 为了评估Galleri MCED测试的现实世界性能.
- 评估测试检测癌症信号和预测癌症信号来源 (CSO) 的能力.
主要方法:
- 对111,080个个体的无细胞DNA甲基化模式的分析.
- 对Galleri MCED测试的癌症信号检测率和CSO预测准确性的评估.
- 追踪检测到癌症信号的个体的临床结果.
主要成果:
- 观察到癌症信号检测率为0.91%,与之前的研究一致.
- 在32种不同类型的258种确诊癌症中,MCED测试在87%的病例中正确预测了CSO.
- 从MCED结果到癌症诊断的中位时间为39.5天,这表明有效的工作.
结论:
- 盖勒里MCED测试在检测癌症信号和预测癌症起源方面证明了现实世界的有效性.
- 该测试有助于有效的诊断评估,可能导致更早的癌症诊断.
- MCED测试对改善人口层面的癌症查具有显著的前景.
更多相关视频
相关概念视频
Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


